Search Results - "BLADE, J"

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network by Terpos, E., Sezer, O., Croucher, P.I., García-Sanz, R., Boccadoro, M., San Miguel, J., Ashcroft, J., Bladé, J., Cavo, M., Delforge, M., Dimopoulos, M.-A., Facon, T., Macro, M., Waage, A., Sonneveld, P.

“…Bisphosphonates (BPs) prevent, reduce, and delay multiple myeloma (MM)-related skeletal complications. Intravenous pamidronate and zoledronic acid, and oral…”
Get full text

Pathogenesis and treatment of renal failure in multiple myeloma by Dimopoulos, M A, Kastritis, E, Rosinol, L, Bladé, J, Ludwig, H

“…Renal failure is a frequent complication in patients with multiple myeloma (MM) that causes significant morbidity. In the majority of cases, renal impairment…”
Get full text

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry by Puig, N, Sarasquete, M E, Balanzategui, A, Martínez, J, Paiva, B, García, H, Fumero, S, Jiménez, C, Alcoceba, M, Chillón, M C, Sebastián, E, Marín, L, Montalbán, M A, Mateos, M V, Oriol, A, Palomera, L, de la Rubia, J, Vidriales, M B, Bladé, J, Lahuerta, J J, González, M, Miguel, J F S, García-Sanz, R

“…We have analyzed the applicability, sensitivity and prognostic value of allele-specific oligonucleotide real-time quantitative PCR (ASO RQ-PCR) as a method for…”
Get full text

International uniform response criteria for multiple myeloma by DURIE, B. G. M, HAROUSSEAU, J.-L, LUDWIG, H, GAHRTON, G, BEKSAC, M, CROWLEY, J, BELCH, A, BOCCADARO, M, TURESSON, I, JOSHUA, D, VESOLE, D, KYLE, R, MIGUEL, J. S, ALEXANIAN, R, TRICOT, G, ATTAL, M, MERLINI, G, POWLES, R, RICHARDSON, P, SHIMIZU, K, TOSI, P, MORGAN, G, RAJKUMAR, S. V, BLADE, J, BARLOGIE, B, ANDERSON, K, GERTZ, M, DIMOPOULOS, M, WESTIN, J, SONNEVELD, P

“…New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow…”
Get full text

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management by Kyle, R A, Durie, B G M, Rajkumar, S V, Landgren, O, Blade, J, Merlini, G, Kröger, N, Einsele, H, Vesole, D H, Dimopoulos, M, San Miguel, J, Avet-Loiseau, H, Hajek, R, Chen, W M, Anderson, K C, Ludwig, H, Sonneveld, P, Pavlovsky, S, Palumbo, A, Richardson, P G, Barlogie, B, Greipp, P, Vescio, R, Turesson, I, Westin, J, Boccadoro, M

“…Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older…”
Get full text

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma by Martinez-Lopez, J, Sanchez-Vega, B, Barrio, S, Cuenca, I, Ruiz-Heredia, Y, Alonso, R, Rapado, I, Marin, C, Cedena, M-T, Paiva, B, Puig, N, Mateos, M-V, Ayala, R, Hernández, M-T, Jimenez, C, Rosiñol, L, Martínez, R, Teruel, A-I, Gutiérrez, N, Martin-Ramos, M-L, Oriol, A, Bargay, J, Bladé, J, San-Miguel, J, Garcia-Sanz, R, Lahuerta, J-J

Get full text

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders by Dispenzieri, A, Kyle, R, Merlini, G, Miguel, J S, Ludwig, H, Hajek, R, Palumbo, A, Jagannath, S, Blade, J, Lonial, S, Dimopoulos, M, Comenzo, R, Einsele, H, Barlogie, B, Anderson, K, Gertz, M, Harousseau, J L, Attal, M, Tosi, P, Sonneveld, P, Boccadoro, M, Morgan, G, Richardson, P, Sezer, O, Mateos, M V, Cavo, M, Joshua, D, Turesson, I, Chen, W, Shimizu, K, Powles, R, Rajkumar, S V, Durie, B G M

“…The serum immunoglobulin-free light chain (FLC) assay measures levels of free κ and λ immunoglobulin light chains. There are three major indications for the…”
Get full text

SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status by López-Corral, L, Sarasquete, M E, Beà, S, García-Sanz, R, Mateos, M V, Corchete, L A, Sayagués, J M, García, E M, Bladé, J, Oriol, A, Hernández-García, M T, Giraldo, P, Hernández, J, González, M, Hernández-Rivas, J M, San Miguel, J F, Gutiérrez, N C

“…Genetic events mediating transformation from premalignant monoclonal gammopathies (MG) to multiple myeloma (MM) are unknown. To obtain a comprehensive genomic…”
Get full text

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial by Rosiñol, L, Oriol, A, Teruel, A I, de la Guía, A L, Blanchard, MaJ, de la Rubia, J, Granell, M, Sampol, MaA, Palomera, L, González, Y, Etxebeste, MaA, Martínez-Martínez, R, Hernández, M T, de Arriba, F, Alegre, A, Cibeira, MaT, Mateos, MaV, Martínez-López, J, Lahuerta, J J, San Miguel, J, Bladé, J

“…The phase III trial GEM05MENOS65 randomized 390 patients 65 years old or younger with newly diagnosed symptomatic multiple myeloma (MM) to receive induction…”
Get full text

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study by San-Miguel, J F, Richardson, P G, Sonneveld, P, Schuster, M W, Irwin, D, Stadtmauer, E A, Facon, T, Harousseau, J-L, Ben-Yehuda, D, Lonial, S, Goldschmidt, H, Reece, D, Bladé, J, Boccadoro, M, Cavenagh, J D, Neuwirth, R, Boral, A L, Esseltine, D-L, Anderson, K C

“…Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for…”
Get full text

Clarification of the definition of complete response in multiple myeloma by Durie, B G M, Miguel, J F S, Blade, J, Rajkumar, S V

Get full text

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials by Arana, P, Paiva, B, Cedena, M-T, Puig, N, Cordon, L, Vidriales, M-B, Gutierrez, N C, Chiodi, F, Burgos, L, Anglada, L-L, Martinez-Lopez, J, Hernandez, M-T, Teruel, A-I, Gironella, M, Echeveste, M-A, Rosiñol, L, Martinez, R, Oriol, A, De la Rubia, J, Orfao, A, Blade, J, Lahuerta, J-J, Mateos, M-V, San Miguel, J-F

“…Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great…”
Get full text

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group by Fernández de Larrea, C, Kyle, R A, Durie, B G M, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Bladé, J, Orlowski, R Z, Shah, J J

“…Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either…”
Get full text

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel by Caers, J, Paiva, B, Zamagni, E, Leleu, X, Bladé, J, Kristinsson, S Y, Touzeau, C, Abildgaard, N, Terpos, E, Heusschen, R, Ocio, E, Delforge, M, Sezer, O, Beksac, M, Ludwig, H, Merlini, G, Moreau, P, Zweegman, S, Engelhardt, M, Rosiñol, L

“…Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary…”
Get full text

Pathogenesis and progression of monoclonal gammopathy of undetermined significance by Bladé, J, Rosiñol, L, Cibeira, M T, de Larrea, C F

“…In Caucasians, monoclonal gammopathy of undetermined significance (MGUS) is an age-related condition with prevalence as high as 3% in persons older than 50…”
Get full text

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control by Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, Miguel, J F San

“…Achieving complete remission (CR) in multiple myeloma (MM) translates into extended survival, but two subgroups of patients fall outside this paradigm: cases…”
Get full text

Differentiation stage of myeloma plasma cells: biological and clinical significance by Paiva, B, Puig, N, Cedena, M T, de Jong, B G, Ruiz, Y, Rapado, I, Martinez-Lopez, J, Cordon, L, Alignani, D, Delgado, J A, van Zelm, M C, Van Dongen, J J M, Pascual, M, Agirre, X, Prosper, F, Martín-Subero, J I, Vidriales, M-B, Gutierrez, N C, Hernandez, M T, Oriol, A, Echeveste, M A, Gonzalez, Y, Johnson, S K, Epstein, J, Barlogie, B, Morgan, G J, Orfao, A, Blade, J, Mateos, M V, Lahuerta, J J, San-Miguel, J F

“…The notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in multiple myeloma (MM) about their phenotypic plasticity…”
Get full text

Management of treatment-emergent peripheral neuropathy in multiple myeloma by Richardson, P G, Delforge, M, Beksac, M, Wen, P, Jongen, J L, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, S V, Harousseau, J L, Moreau, P, Avet-Loiseau, H, Lee, J H, Cavo, M, Merlini, G, Voorhees, P, Chng, W J, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, J J, Niesvizky, R, Siegel, D, Mateos, M-V, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, J San, Morgan, G, Anderson, K C, Durie, B G M, Sonneveld, P

“…Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects…”
Get full text

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma by Palumbo, A, Rajkumar, S V, Dimopoulos, M A, Richardson, P G, San Miguel, J, Barlogie, B, Harousseau, J, Zonder, J A, Cavo, M, Zangari, M, Attal, M, Belch, A, Knop, S, Joshua, D, Sezer, O, Ludwig, H, Vesole, D, Bladé, J, Kyle, R, Westin, J, Weber, D, Bringhen, S, Niesvizky, R, Waage, A, von Lilienfeld-Toal, M, Lonial, S, Morgan, G J, Orlowski, R Z, Shimizu, K, Anderson, K C, Boccadoro, M, Durie, B G, Sonneveld, P, Hussein, M A

“…The incidence of venous thromboembolism (VTE) is more than 1‰ annually in the general population and increases further in cancer patients. The risk of VTE is…”
Get full text

Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma by Fernández de Larrea, C, Jiménez, R, Rosiñol, L, Giné, E, Tovar, N, Cibeira, M T, Fernández-Avilés, F, Martínez, C, Rovira, M, Bladé, J

“…The achievement of CR is the crucial step for a prolonged PFS and OS after an autologous SCT in multiple myeloma (MM). Unfortunately, even with the use of new…”
Get full text